Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity

Journal of Clinical Oncology

Volumn 18, Issue 10, 2000, Pages 2116-2125

  Venturini, Marco ^a   Lunardi, Gianluigi ^a   Del Mastro, Lucia ^a   Vannozzi, Maria Ornella ^a   Tolino, Giuseppina ^a   Numico, Gianmauro ^a   Viale, Maurizio ^a   Pastrone, Ilaria ^a   Angiolini, Catia ^a   Bertelli, Gianfilippo ^a   Straneo, Manuela ^a   Rosso, Riccardo ^a   Esposito, Mauro ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; PACLITAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

EID: 0034071001     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.10.2116     Document Type: Article

References (23)

1. Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial. Proc Am Soc Clin Oncol 16:1a. 1997 (abstr 2)
2. Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996
3. Holmes FA, Valero V, Walters RS, et al: Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer. Ann Oncol 10:403-411, 1999
4. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
5. Gianni L, Viganò L, Locatelli A, et al: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915, 1997
6. Conte PF, Baldini E, Gennari A, et al: Dose finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15:2510-2517, 1997
7. Esposito M, Venturini M, Vannozzi MO, et al: Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 17:1132-1140, 1999
8. Gianni L, Viganò L, Locatelli A, et al: Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI). Proc Am Soc Clin Oncol 16:224a, 1997 (abstr 786)
9. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
10. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
11. Garrone O, Angiolini C, Bergaglio M, et al: Paradoxical effect of paclitaxel on neutrophils and platelets recovery after standard dose chemotherapy. Proc Am Soc Clin Oncol 17:142a, 1998 (abstr 543)
12. Sledge GW, Robert N, Sparano JA, et al: Paclitaxel/doxorubicin combination in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994 (suppl 8)
13. Chan KK, Chlebowski RT, Tong M, et al: Clinical pharmacokinetics of Adriamycin in hepatoma patients with cirrhosis. Cancer Res 40:1263-1268, 1980
14. Cassinelli G, Configliacchi E, Penco S, et al: Separation and characterization and analysis of epirubicin (4′-epidoxorubicin) and its metabolites from human urine. Drug Metab Dispos 12:4-20, 1984
15. Webster L, Linsermeyer M, Millward M, et al: Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685-1690, 1993
16. Rischin D, Webster LK, Millward MJ, et al: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88:1297-1301, 1996
17. Marsh JC: The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: A review. Cancer Res 36:1853-1882, 1976
18. Botnick LE, Hannon EC, Vigneulle R, et al: Different effects of cytotoxic agents on hematopoietic progenitors. Cancer Res 41:2338-2342, 1981
19. Jakobsen P, Bastholt L, Dalmark M, et al: A randomized study of epirubicin at four different dose levels in advanced breast cancer: Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28:465-469, 1991
20. Madden T, Newman RA, Antoun G, et al: Paclitaxel effects on topoisomerase II transcription and activity in human breast cancer cell lines. Proc Am Assoc Cancer Res 37:358, 1996 (abstr 2446)
21. Yosef H, Slater A, Keen CW, et al: Prednimustine (sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer 29A:1100-1105, 1993
22. Saarto T, Blomqvist C, Rissanen P, et al: Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301-305, 1997
23. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996